SION · Sionna Therapeutics, Inc. · Executive Compensation
$3.87
+0.18 (+4.88%)
At close · Oct 27
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. The Company believes that its existing cash, cash equivalents and marketable securities of $268.3 million as of June 30, 2026, will be sufficient to allow the Company to fund operations beyond twelve months from the date that the financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$165.93M
Shares
45.21M
Volume · Oct 27
1M
Avg daily vol (3M)
2.25M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Michael Cloonan | M.B.A. President and Chief Executive Officer | $6,981,217 |
| Caroline Stark Beer | M.B.A. Chief Business Officer | $5,592,896 |
| Elena Ridloff | C.F.A. Chief Financial Officer | $2,857,367 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Michael Cloonan | M.B.A. Chief Executive Officer | $3,726,785 |
| Elena Ridloff | C.F.A. Chief Financial Officer and Head of Corporate Development | $1,300,647 |
| Charlotte McKee | Chief Medical Officer | $1,283,240 |
| Caroline Stark Beer | M.B.A. Chief Business Officer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Michael Cloonan | M.B.A. Chief Executive Officer | $754,416 |
| Charlotte McKee | Chief Medical Officer | $623,002 |
| Elena Ridloff | C.F.A. Chief Financial Officer and Head of Corporate Development | $623,002 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Elena Ridloff | Chief Business Officer | Appointed | 2026-09-14 |
| Caroline Stark Beer, M.B.A. | Chief Business Officer | Terminated | 2026-09-14 |
Leadership
- Michael Cloonan CEO
- Elena Ridloff CFO
- H. Edward Fleming Board Member
- Joanne Louise Viney Board Member
- Marcella Kuhlman Ruddy Board Member
- Peter A. Thompson Board Member
Key facts
CIK
2036042
CUSIP
829401108
13F (30d)
16 filings
16 filers
Visit website
Investor relations